BioTuesdays
Acasti Pharma

Mackie puts Acasti Pharma under review; removes PT

Mackie Research Capital put Acasti Pharma (NASDAQ, TSXV:ACST) “under review” and removed its price target after the company’s pivotal TRILOGY-1 trial missed its primary endpoint because of an unexplained high placebo...

Subscribe

Sign up to our weekly BioTuesdays newsletter.